Figure 2.

Screening Chart. Chart shows our strategy of producing and screening various DTEGF13 mutants on the path to deimmunization. In phase 1, 8 triple mutants were synthesized and purified. Four of these showed less than a log of activity loss in our in vitro screening assay compared to the non-mutated parental control. In phase 2, mutations were combined to generate a quintuple mutant that still had less than a log of activity loss compared to parental. These are marked with an asterisk (*) in the figure. In phase 3, we analyzed a septuplet mutant that still had less than a log of activity loss. Glycine, alanine, and serine substitution were employed.